Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥60 Gy) and factors influencing consideration for surgery in stage III non-s...

by Melissa A.L. Vyfhuis, MD PhD, Neha Bhooshan, MD PhD, Whitney M. Burrows, MD, Michelle Turner, NP, Mohan Suntharalingam, MD MBA, James Donahue, MD, Elizabeth M. Nichols, MD, Josephine Feliciano, MD, Søren M. Bentzen, PhD DMSc, Shahed Badiyan, MD, Shamus R. Carr, MD, Joseph Friedberg, MD, Charles B. Simone, II, MD, Martin J. Edelman, MD, Steven J. Feigenberg, MD, Pranshu Mohindra, MD
Published 2017-07-01